NASDAQ:DMPI - DelMar Pharmaceuticals, Inc.
$1.44
 $0.01
+0.91%
4:00PM EDT
2019-07-15
DelMar Pharmaceuticals, Inc., incorporated on June 24, 2009, is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications.VAL-083 represents a small molecule chemotherapeutic approved for the treatment of cancer. As of June 30, 2016, VAL-083 had been assessed in 42 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI) in the United States as a treatment against various cancers, including lung, brain, cervical, ovarian tumors and leukemia. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  DMPI     avg for
industry  
  avg for
sector  
42 stocks weight:  1. 00   114. 77   204. 78  
42 stocks rank:  4. 45 K 1. 44 K 810. 33  
# analyst opinions:  1. 00   13. 59   13. 86  

quick ratio:  1. 80   5. 48   1. 89  
current ratio:  2. 04   5. 85   2. 40  

target price low:  1. 20   82. 72   115. 11  
target price avg:  1. 20   104. 42   138. 02  
target price high:  1. 20   130. 64   159. 47  
1-yr high:  8. 20   110. 27   142. 72  
last close:  1. 43   85. 12   126. 54  
50-day avg:  2. 09   86. 06   122. 35  
200-day avg:  4. 02   88. 76   121. 75  
1-yr low:  1. 19   69. 26   100. 63  
volume:  49. 11 K 3. 51 M 5. 53 M
50-day avg volume:  337. 64 K 3. 21 M 4. 22 M
200-day avg volume:  97. 51 K 3. 04 M 4. 75 M

1-day return:  -3. 38 % -0. 30 % -1. 01 %
this week return:  -6. 54 % -2. 16 % -1. 35 %
12-wk return:  -60. 93 % 3. 34 % 8. 69 %
52-wk return:  -77. 60 % -1. 76 % 12. 22 %

enterprise value (EV):  7. 71 M 46. 50 B 123. 99 B
market cap:  5. 31 M 40. 77 B 109. 11 B
total debt:  0. 00   11. 27 B 17. 58 B
net income (common):  -7. 95 M 2. 13 B 4. 27 B

shares outstanding:  22. 01 M 551. 08 M 1. 24 B
shares:  2. 10 M 559. 41 M 1. 22 B
shares short:  126. 75 K 11. 15 M 11. 94 M
shares short prior month:  51. 14 K 9. 31 M 11. 96 M
short ratio:  0. 24   5. 72   3. 43  
short % of float:  5. 03 % 6. 40 % 2. 65 %
total cash/share:  0. 81   11. 00   9. 23  
total cash:  2. 15 M 6. 03 B 6. 01 B
free cash flow:  -4. 15 M 3. 02 B 4. 96 B
operating cash flow:  -7. 05 M 3. 92 B 5. 99 B

book value:  -1. 86   13. 02   27. 49  
price/book:  -0. 77   4. 21   8. 80  
operating margins:  0. 00 % -380. 20 % -38. 44 %
EBITDA margins:  0. 00 % 13. 59 % 23. 24 %
profit margins:  0. 00 % 10. 94 % 14. 00 %
gross margins:  0. 00 % 36. 11 % 55. 16 %

1-yr max volatility:  141. 73 % --- ---
1-yr mean volatility:  5. 28 % 1. 50 % 1. 08 %

1-yr EPS:  -3. 31   2. 12   4. 26  
P/E:  -0. 43   2. 15   33. 17  
PE/G:  0. 01   0. 54   0. 34  
growth:  -56. 66 % 263. 03 % 78. 34 %
earnings high:  -0. 00   0. 91   1. 70  
earnings avg:  -0. 00   0. 71   1. 58  
earnings low:  -0. 00   0. 48   1. 46  
revenue high:  -0. 00   2. 64 B 11. 26 B
revenue avg:  -0. 00   2. 58 B 11. 09 B
revenue low:  -0. 00   2. 54 B 10. 90 B
return on assets:  -81. 45 % -2. 31 % 5. 31 %
return on equity:  -175. 87 % -82. 48 % 135. 30 %

beta (1yr vs S&P500):  0. 80   1. 26   0. 91  
sharpe (1yr):  -0. 18   0. 07   0. 77  

held % insiders:  7. 73 % 6. 08 % 3. 31 %
held % institutions:  7. 86 % 78. 36 % 69. 61 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-14 : DMPI
.    101.121 =       101.121 :: --> INITIAL WEIGHT <--
.    - 3.306 =        97.815 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.949 =       190.607 :: P/E factor
.    x 2.209 =       421.042 :: PE/G factor
.    x 1.264 =       532.359 :: beta factor
.      x 0.7 =       372.879 :: sharpe factor
.    x 2.348 =       875.639 :: current ratio factor
.    x 1.454 =      1273.312 :: quick ratio factor
.    x 2.019 =      2571.029 :: short ratio factor
.                               --> PERFORMANCE <--
.    x 2.114 =      5435.115 :: sector+industry 1-year gains factor
.    x 1.033 =      5616.637 :: industry 12-weeks return factor
.    x 1.305 =      7331.248 :: industry 2-weeks return factor
.    / 2.359 =      3108.078 :: overall "drift" factor
.      x 0.0 =         1.305 :: largest single-day jump factor
.    x 0.063 =         0.083 :: low price factor
.    x 0.045 =         0.004 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.365 =         0.001 :: forward P/E factor
.    x 1.182 =         0.002 :: industry recommendation factor
.    x 1.008 =         0.002 :: factor historical industry gain for week 28
.                               --> FINAL ADJUSTMENTS <--
.      + 1.0 =         1.002 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      1.002 :: FINAL WEIGHT for NASDAQ:DMPI


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org